OPKO Health, Inc. - 10-Q Summary (Q1 2008)
Business Context and Reporting Period
This report covers the quarterly period ended March 31, 2008. OPKO Health, Inc. is a specialty healthcare company focused on ophthalmic pharmaceuticals, imaging, and diagnostic systems. The company operates through its subsidiaries, including Ophthalmic Technologies, Inc. (OTI), acquired in November 2007. As of May 1, 2008, the company had 183,163,265 shares of common stock outstanding.
Key Financial Metrics
| Metric | Q1 2008 | Q1 2007 |
|---|---|---|
| Revenue | $2.82 million | $0 |
| Gross Margin (Deficit) | ($0.51) million | $0 |
| Net Loss | ($10.88) million | ($249.94) million |
| Net Loss Attributable to Common Shareholders | ($10.94) million | ($249.95) million |
| Loss Per Share (Basic & Diluted) | ($0.06) | ($3.87) |
| Cash and Cash Equivalents (End of Period) | $14.64 million | $17.08 million |
| Net Cash Used in Operating Activities | ($6.56) million | ($0.46) million |
| Total Debt (Current + Long-term + Line of Credit) | $22.02 million | N/A (Prior period structure differed) |
Note: Q1 2007 results were heavily impacted by a $243.8 million write-off of acquired in-process research and development related to the Acuity Pharmaceuticals acquisition.
Material Changes vs. Prior Period
- Revenue Generation: The company generated $2.82 million in revenue in Q1 2008, compared to zero in Q1 2007. All revenue was derived from OTI's ophthalmic instrumentation sales, primarily international.
- Operating Expenses: Total operating expenses decreased significantly to $10.13 million from $249.92 million in the prior year. This reduction is primarily due to the absence of the $243.8 million non-cash write-off recorded in 2007.
- Debt Repayment: The company repaid $2.4 million in January 2008 to fully satisfy a $4.0 million term loan with Horizon Financial Funding Company, LLC.
- Stock-Based Compensation: Stock-based compensation expense was $2.73 million in Q1 2008, compared to $6.04 million in Q1 2007. The 2007 figure included a reversal of $5.9 million related to a terminated consulting agreement.
Guidance, Outlook, Risks, and Unusual Items
- Liquidity Warning: Management explicitly states that cash on hand ($14.6 million) is not sufficient to meet anticipated cash requirements for operations and debt service for the next 12 months. Additional funding is required in the second half of 2008.
- FDA Warning Letter: In March 2008, OTI received an FDA warning letter regarding deficiencies in quality and record-keeping at its Toronto facility. This resulted in an Import Alert, preventing the sale of certain devices (OTI Scan 1000, 2000, and OCT/SLO) in the U.S. until violations are corrected. The company is reimbursing customers for limited units shipped prior to the alert.
- Legal Proceedings: Ophthalmic Imaging Systems (OIS) filed a lawsuit seeking over $7 million in damages against the company and related parties (The Frost Group) for tortious interference. The company intends to vigorously defend the claims.
- Subsequent Event: On May 6, 2008, the company acquired Vidus Ocular, Inc., developer of the Aquashunt glaucoma treatment, in exchange for common stock and options.
- Outlook: The company expects to continue incurring substantial losses as it advances the Phase III clinical trial for bevasiranib and expands its sales infrastructure. Revenue is anticipated to decrease in Q2 2008 as production of OCT/SLO components moves in-house.
Investor Verification Checklist
- Verify the timeline and cost implications of resolving the FDA warning letter and Import Alert for OTI products.
- Confirm the status and terms of the planned capital raise required to fund operations for the next 12 months.
- Monitor the progress of the $7 million+ lawsuit filed by Ophthalmic Imaging Systems.
- Review the integration and milestone achievements of the Vidus Ocular acquisition completed in May 2008.
- Assess the impact of the U.S. sales ban on the OCT/SLO device on Q2 and Q3 revenue projections.